Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)(Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)) - 在研适应症：流感病毒感染，甲型流感病毒感染，乙型流感病毒感染_专利_临床

概要

基本信息

药物类型

灭活疫苗、预防性疫苗、多价疫苗

别名

a-RIX-Tetra、FLU D-QIV、Fluarix Tetra

+ [11]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染甲型流感病毒感染乙型流感病毒感染

非在研适应症-

原研机构

GSK Plc

在研机构

GlaxoSmithKline Biologicals SA

GSK Plc

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2005-08-31),

甲型流感病毒感染乙型流感病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

71

项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的临床试验

NCT05648357

/ Completed临床4期

A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.

开始日期2023-12-14

申办/合作机构

GSK Plc

NCT05734040

/ Completed临床2期

Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.

The present study OVX836-006 aims principally to:
* Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms;
* Introduce an additional representative brand of Quadrivalent Inactivated Influenza Vaccines ;
* Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the Hemagglutinin response;
* Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the nucleoprotein response;
* Evaluate the absolute vaccine efficacy of OVX836 compared to placebo in order to corroborate the efficacy signals previously detected in the OVX836 previous studies;
* Evaluate the combined vaccine efficacy of OVX836 + Quadrivalent Inactivated Influenza Vaccines versus OVX836 + placebo, and versus double placebo.

开始日期2023-05-10

申办/合作机构

Osivax SAS

[+2]

CTRI/2022/12/048070

/ Completed临床4期

A single-arm, open-label, multi-center, phase IV trial to evaluate the reactogenicity, safety, and immunogenicity of quadrivalent seasonal influenza vaccine (Fluarix Tetra) in participants aged 65 years and older in India

开始日期2022-12-20

申办/合作机构

GlaxoSmithKline Biologicals SA

[+1]

100 项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

128

项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的文献（医药）

2026-02-01·VACCINE

Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial

Article

作者: Walter, Emmanuel B ; Davis, Grace N ; Broder, Karen R ; Schlaudecker, Elizabeth P ; Montefiori, David ; Spreng, Rachel L ; Rountree, Wes ; Tekalign, Rediet ; Poniewierski, Marek S ; Goel, Anju ; Schmader, Kenneth E ; Staat, Mary A ; Duffy, Jonathan ; Talaat, Kawsar R ; Museru, Oidda

BACKGROUND:

A U.S. multisite trial was conducted and explored whether blunting of mRNA COVID-19 vaccine immunogenicity occurred when administered simultaneously with influenza vaccine.

METHODS:

Persons ≥5 years of age received either quadrivalent inactivated influenza vaccine (IIV4) or saline placebo simultaneously with an initial or booster dose of mRNA COVID-19 vaccine. Those receiving placebo with mRNA COVID-19 vaccine received IIV4 7-14 days later. SARS-CoV-2 antibody was assessed by pseudovirus neutralization (D614G, BA.4/BA. 5, and XBB.1.5) at baseline and 28 days following mRNA COVID-19 vaccine primary series or booster dose.

RESULTS:

Of 335 randomized participants, 157 were in the simultaneous group and 150 the sequential group. Post-vaccination geometric mean SARS-CoV-2 ID50 titers for the ancestral D614G strain and BA.4/5 variant (simultaneous versus sequential) were 4357.1 versus 4492.3(p = 0.79) and 1547.8 versus 1463.8(p = 0.69), respectively.

CONCLUSION:

Blunting of mRNA COVID-19 vaccine immunogenicity was not observed when mRNA COVID-19 and influenza vaccines were administered simultaneously. TRIAL REGISTRATIONClinicalTrials.gov ID: NCT05028361.

2026-01-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial

Article

作者: Duca, Lindsey M ; Soto, Giselle ; Gonzales, Miriam ; Romero, Candice ; Prouty, Michael ; Romero, Fiorela Alvarez ; Fowlkes, Ashley ; Díaz, Roger A Hernández ; Levine, Min Z ; La Rosa, Sayda ; Prado, Eduardo D Matos ; Marcenac, Perrine ; Arriola, Carmen Sofia ; Azziz-Baumgartner, Eduardo ; Neyra, Joan ; Silva, Maria ; Yau, Tat ; Llanos-Cuentas, Alejandro ; Carreon, Joseph Daniel

OBJECTIVES:

We conducted a randomized controlled trial to evaluate whether adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) generates superior immunogenicity against influenza viruses compared to conventional quadrivalent inactivated influenza vaccine (IIV4) among healthcare personnel (HCP) in Lima, Peru.

METHODS:

During 2022-2023, we randomized 192 HCP aged ≥18 years to receive 2022 Southern Hemisphere IIV4 or aIIV4 and collected pre-, 1-month post-, and 6-months post-vaccination sera. Geometric mean titers (GMTs), GMT ratios, seroconversion rates (SCR), and seroprotection rates (SPR) were compared against vaccine reference viruses-influenza A(H1N1)pdm09, A(H3N2), B/Victoria, and B/Yamagata-using hemagglutination inhibition assays.

RESULTS:

Most HCP (77-99%) had titers ≥40 following vaccination. One-month post-vaccination, aIIV4 induced higher GMTs (GMT ratio: 1.7 [95% confidence interval 1.1-2.7]) and SCR (88.4% [80.4-93.4] vs 62.1% [52.1-71.2]) against A(H1N1)pdm09 and higher SCR (82.1% [73.2-88.5] vs 62.1% [52.1-71.2]) against A(H3N2) compared to IIV4. At 6 months, aIIV4 induced higher SPR against A(H3N2) (90.4% [82.8-94.9] vs 74.0% [64.4-81.7]) than IIV4. IIV4 recipients vaccinated the preceding influenza season had lower odds of seroconverting to A(H1N1)pdm09 compared to IIV4 recipients who were not vaccinated (adjusted odds ratio: 0.29 [0.13-0.63], P = 0.002).

CONCLUSION:

These findings provide insights into the benefits of an enhanced influenza vaccine (aIIV4) to help overcome the immune blunting effects of repeat vaccination among HCP.

CLINICAL TRIALS REGISTRATION:

NCT06054269.

2025-12-31·Human Vaccines & Immunotherapeutics

Reactogenicity, safety, and immunogenicity of a quadrivalent seasonal influenza vaccine in adults aged 65 years and older: Phase 4 study results from India during December 2023–February 2024

Article

Fluarix Tetra is a quadrivalent seasonal influenza vaccine that has been approved in India for immunization of adults and children aged ≥6 months. This study was conducted in adults aged ≥65 years in India to fulfill a post-approval regulatory commitment. In this prospective, multicenter, single-arm, open-label, Phase 4 study, participants were administered a single 0.5-mL dose of Fluarix Tetra (2023-2024 Northern Hemisphere). The primary objectives were to assess the reactogenicity and safety of Fluarix Tetra by monitoring solicited adverse events (AEs) within 7 days post-vaccination, as well as unsolicited AEs and serious AEs (SAEs) within 21 days post-vaccination. The secondary objective was to evaluate immunogenicity by monitoring the geometric mean titers, geometric mean increase, seroconversion rates (SCRs), and seroprotection rates (SPRs). Overall, 250 adults aged ≥65 years (mean age, 71.8 years) were included in the study. Pain (15.0%) was the most common solicited injection-site AE, and fever (6.5%) was the most common solicited systemic AE. No SAEs were reported within the 21-day post-vaccination period, and no deaths occurred during the study. The hemagglutination inhibition titers increased from Day 1 to Day 22 against all the four influenza strains, A/(H1N1), A/(H3N2), B/Yamagata, and B/Victoria, with SPRs > 80% and SCRs > 75% at Day 22. Fluarix Tetra was well tolerated and immunogenic in adults aged ≥65 years in India.Trial registration: NCT05648357.

68

项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的新闻（医药）

2026-01-16

·生物制品圈

FDA 要求流感疫苗增列儿童惊厥风险警告

摘要：2026 年1月初，美国 FDA 向赛诺菲、葛兰素史克、阿斯利康和 CSL 四大药企发出通知，要求其 6 款流感疫苗标签新增发热性惊厥风险警告。这一要求源于两项上市后观察研究，数据显示 6 个月至 4 岁儿童接种后首日风险上升。目前药企正回应要求，而此前 CDC 刚调整儿童免疫规划，流感疫苗相关争议再起。四大药企接通知，疫苗标签要更新本月 9 日，FDA 向赛诺菲、阿斯利康、葛兰素史克和 CSL Seqirus 四家药企同步发出标签修改通知。涉及的 6 款疫苗都是美国市场的 “老面孔”，最短上市时间也有 13 年，其中赛诺菲的 Fluzone 早在 1980 年就获批，阿斯利康的 FluMist、葛兰素史克的 Fluarix 等也都是临床常用款。 FDA 在通知中明确，旗下生物制品有效性与安全系统（BEST）开展的两项研究发现，6 个月至 4 岁儿童接种后 0-1 天内，发热性惊厥的发生风险比接种后 8-63 天的对照期有所增加。从 2023-2025 两个流感季的保险理赔数据来看，四价疫苗每百万剂约出现 21 例惊厥，三价疫苗这一数字则为 44 例。药企回应各异，安全争议持续面对 FDA 的要求，各家药企反应不一。赛诺菲发言人表示，Fluzone 已累计接种数十亿剂，惊厥仅发生在 “极少数患者” 中，且现有处方信息已包含相关说明，同时强调疫苗的安全性和有效性有充分数据支撑。葛兰素史克则称正审核 FDA 的请求，始终将患者安全放在首位，对自家流感疫苗的安全性充满信心。 FDA 给药企设定了 30 天的回应期限，企业可选择同意修改、提议调整或提交反驳意见说明无需修改的理由。值得一提的是，发热性惊厥通常持续不超过几分钟，对儿童健康一般无长期危害，这也让部分家长对警告的必要性产生了讨论。免疫规划大调整，行业担忧风险上升这一标签修改要求来得颇为凑巧 —— 就在本月初，CDC 刚对儿童免疫规划进行了大幅调整，不仅取消了儿童流感疫苗的普遍推荐，还删减了新冠病毒、轮状病毒等多种疫苗的常规接种建议。原本针对婴幼儿住院首要原因的 RSV 疫苗，如今也仅面向高危群体和母亲未接种的儿童开放。背后的行业背景耐人寻味，自长期反对疫苗的罗伯特・肯尼迪 Jr. 执掌卫生与公众服务部后，疫苗领域的监管审查明显收紧。去年他还撤换了 CDC 免疫实践咨询委员会的全部 17 名专家，引发行业震动。赛诺菲方面提醒，流感对 5 岁以下幼儿和有基础疾病的人群风险不小，美国儿科学会仍建议 6 个月以上无禁忌的儿童每年接种流感疫苗。传染病专家则担忧，取消普遍接种推荐再叠加标签新增警告，可能让部分高风险儿童错过保护，增加并发症风险。这场疫苗安全与接种覆盖率的平衡之战，还在持续发酵。参考来源：https://www.fiercepharma.com/pharma/fda-tells-sanofi-gsk-az-and-csl-include-warning-childhood-seizures-flu-shots 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

2026-01-13

·EndPoints

FDA asks flu vaccine makers to update labels to flag risk of febrile seizures

The FDA asked manufacturers of a half-dozen flu vaccines to update their labels to mention the risk of febrile seizures, which are convulsions caused by fevers in young children. In letters last Friday, the agency said its decision to update the labels was based on data from the 2023-2024 and 2024-2025 seasons as it looked into three commercial insurance claims data sources in self-controlled case series analyses. The review identified “significantly increased risks of febrile seizures in the first day following influenza vaccination,” the letters say . The targeted products included GSK’s Flulaval and Fluarix, AstraZeneca’s FluMist, CSL Seqirus’ Afluria and Flucelvax, and Sanofi’s Fluzone. The companies didn’t immediately respond to requests for comment. The FDA proposed updating the labels to add that an observational study it ran suggests “a causal relationship between standard dose influenza quadrivalent and trivalent vaccines and febrile seizures in children 6 months through 4 years of age.” The letters come as the FDA last summer began work on a new flu vaccine framework, which a senior FDA official told Endpoints News would address “a lot of problems” related to strain selection, year-over-year changes in efficacy, and the specific assays to evaluate effectiveness that are “a little antiquated.” The move toward a new flu framework comes as FDA Commissioner Marty Makary also has predicted a universal flu vaccine will be available within the next five years, “including potential bird flu variants.” Clinical trials for universal flu vaccines are expected to begin this year, with FDA approval targeted for 2029, according to HHS.

疫苗上市批准

2026-01-05

·医药笔记

Moderna：流感mRNA疫苗递交上市申请

▎Armstrong 2025年1月5日，Moderna宣布已经递交流感mRNA疫苗mRNA-101的上市申请，包括美国、欧盟、加拿大、澳大利亚等。此次上市申请是依据多个三期临床数据，P304三期临床中相对有效率为26.6%，65岁以上人群亚组相对有效率为27.4%。P303三期临床中达到更高的血清转化率和中和抗体滴度。 Moderna当天股价涨4%，目前市值为126亿美元。 P304三期临床于2024年9月启动，计划入组56000例50岁以上受试者，于2025年底完成。 mRNA1010一共开展了四项三期临床，P304与Fluarix头对头比较，第一个流行季34000例，第二个流行季22000例，主要终点为比较mRNA-1010与阳性对照的保护率。前的三期临床P303已经达到主要终点，免疫原性优于Fluzon HD。安全性方面，mRNA-1010表现出可耐受性，但reactogenicity比Fluzone HD更高。总结很长时间以来，赛诺菲的灭活流感疫苗和重组流感疫苗统治市场，Moderna寄望于mRNA疫苗可以颠覆其地位。2025年3月，黑石生命科学投资7.5亿美元到Moderna的流感mRNA疫苗，换取商业里程碑金额以及低个位数的销售分成。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

信使RNA临床3期疫苗抗体药物偶联物临床1期

100 项与 Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	澳大利亚	GSK Plc	2013-08-28
甲型流感病毒感染	美国	GlaxoSmithKline Biologicals SA	2005-08-31
乙型流感病毒感染	美国	GlaxoSmithKline Biologicals SA	2005-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05648357 (Pubmed \| Hum Vaccin Immunother)	临床4期	流感病毒感染	250	Fluarix Tetra	獵積願觸鹹壓齋築選遞(製夢簾遞製積鹹鏇鑰衊) = 鑰艱夢齋築繭鹽齋顧鬱齋淵選積廠醖鏇鏇衊膚 (襯範選窪觸膚簾襯廠窪 ) 更多	积极	2025-12-31
NCT05648357 (CTgov)	临床4期	流感病毒感染	250	Fluarix Tetra Vaccine	獵鏇衊蓋醖築觸觸構夢 = 壓窪淵淵壓襯壓築衊獵鏇齋夢夢範夢襯鏇選鏇 (製齋選衊夢壓艱願窪蓋, 鹽繭構築獵顧膚選憲鑰 ~ 襯齋範憲構糧餘夢構衊) 更多	-	2025-03-28
NCT05047770 (Pubmed) 人工标引	临床3期	带状疱疹	497	mRNA-1273quFlu D-QIVt influenza vaccine (QIV)	蓋觸網齋觸糧觸積簾鏇(鏇繭鬱膚壓餘願夢鹽餘) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. 簾觸遞憲網顧製齋遞齋 (願鏇廠壓廠憲簾蓋膚願 ) 更多	非劣	2024-12-31
				mRNA-1273 + Flu D-QIV(CoAd )
NCT03722589 (CTgov)	临床4期	流感病毒感染	944	Flublok (Flublok (Recombinant))	齋蓋膚鏇製窪構鬱鑰繭 = 獵鑰選憲簾簾壓夢蓋壓觸廠醖鹽觸膚醖製衊蓋 (網網簾淵願繭網鬱構襯, 繭夢獵範蓋簾繭襯簾糧 ~ 簾築憲築餘夢鹹蓋鹹鹹) 更多	-	2024-07-22
				Flucelvax (Flucelvax (Cell-based))	齋蓋膚鏇製窪構鬱鑰繭 = 膚簾網淵淵齋願膚糧餘觸廠醖鹽觸膚醖製衊蓋 (網網簾淵願繭網鬱構襯, 遞鑰網製襯鬱醖齋糧範 ~ 壓壓獵構鬱繭範築遞顧) 更多
NCT05045144 \| EUCTR2021-000357-26-ES (Pubmed)	临床3期	-	1,415	RSVPreF3 vaccine lot 1	鏇衊壓艱築醖遞鏇鹹廠(夢膚憲觸襯願積網鹽鑰) = Co-administration was well tolerated, and both vaccines had clinically acceptable safety and reactogenicity profiles 鏇淵範餘窪壓製艱襯艱 (鏇襯選構襯獵齋鹹範願 )	积极	2024-07-05
				RSVPreF3 vaccine lot 2
NCT02707692 (CTgov)	N/A	获得性免疫缺陷综合征	54	placebo+Pneumovax-23 (Pneumococcal Vaccine)	鏇醖鑰襯構鹽構壓顧窪(範鹽獵鏇簾選齋築衊鹹) = 選窪艱觸襯築網構膚顧齋願築齋餘餘夢襯夢鑰 (獵醖選積簾構遞鹹衊鹹, 2998.0)	-	2022-08-24
				Fluarix+placebo (Influenza Vaccine)	鏇醖鑰襯構鹽構壓顧窪(範鹽獵鏇簾選齋築衊鹹) = 製遞艱鑰觸鹽製膚範鹹齋願築齋餘餘夢襯夢鑰 (獵醖選積簾構遞鹹衊鹹, 243.2) 更多
NCT03686514 (FLU2, CTgov)	临床4期	流感病毒感染	39	seasonal influenza vaccine (H3N2 Birth Cohort, Born Between 1968 and 1977)	獵憲夢齋糧膚醖繭醖範 = 糧鑰醖襯選積構顧觸齋製獵簾築淵餘窪膚廠壓 (網膚遞遞廠築鹹構衊顧, 淵鬱鹽範膚觸襯齋簾廠 ~ 製膚構鹹獵鑰鬱觸願積) 更多	-	2022-07-13
				seasonal influenza vaccine (H1N1 Birth Cohort, Born Between 1948 and 1957)	獵憲夢齋糧膚醖繭醖範 = 製構淵鏇簾顧餘築醖壓製獵簾築淵餘窪膚廠壓 (網膚遞遞廠築鹹構衊顧, 遞繭衊觸夢鑰鹹積顧獵 ~ 積範遞鹹鹽壓廠範積選) 更多
NCT03701061 (HIPCVAX-010S, CTgov)	临床4期	H5N1流感	12	Seasonal Influenza Vaccine (Participants That Received AS03 Adjuvant)	鏇簾艱積糧獵簾範糧繭 = 衊繭廠壓顧獵鏇廠願壓廠範願鹽醖築壓壓夢壓 (選糧鬱範顧積齋壓選鑰, 壓廠製糧夢鬱構廠鏇窪 ~ 選壓夢簾鑰淵窪選顧繭) 更多	-	2020-03-11
				Seasonal Influenza Vaccine (Participants That Did Not Receive AS03 Adjuvant)	鏇簾艱積糧獵簾範糧繭 = 壓繭衊憲觸衊選築觸顧廠範願鹽醖築壓壓夢壓 (選糧鬱範顧積齋壓選鑰, 膚製餘構窪膚衊鏇醖蓋 ~ 範觸範夢醖網鬱壓築選) 更多
NCT01439360 (Pubmed \| Pediatr Infect Dis J)	临床3期	流感病毒感染	12,046	Inactivated Quadrivalent Influenza Vaccine (IIV4)	蓋構艱鹹願網蓋構憲夢(蓋簾夢觸壓製壓築顧蓋) = 46% less frequent following vaccination with IIV4 than with control 製憲範憲憲壓夢製鏇遞 (範構憲築齋襯衊製簾窪 ) 更多	-	2019-08-01
				Inactivated Quadrivalent Influenza Vaccine (Control)
NCT03165981 (CTgov)	临床4期	热性惊厥 \| 发热 \| 接种疫苗	221	IIV+DTaP+PCV13 (Simultaneous Vaccination Arm)	糧蓋餘構製醖範構製獵 = 壓鹽築壓淵鏇憲醖鑰鑰願簾網壓顧膚餘壓鑰醖 (窪憲淵壓獵艱築憲窪鬱, 簾範網艱鏇蓋壓範蓋築 ~ 廠簾衊獵餘齋製範衊積) 更多	-	2019-02-08
				IIV+DTaP+PCV13 (Sequential Vaccination Arm)	糧蓋餘構製醖範構製獵 = 衊窪鬱鑰顧範艱鬱鹹積願簾網壓顧膚餘壓鑰醖 (窪憲淵壓獵艱築憲窪鬱, 簾壓願襯襯鏇醖鏇築衊 ~ 廠艱憲鏇繭醖選選蓋獵) 更多